Cargando…

Sacituzumab govitecan for breast cancer

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: NPS MedicineWise 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9427618/
https://www.ncbi.nlm.nih.gov/pubmed/36110167
http://dx.doi.org/10.18773/austpresr.2022.042
_version_ 1784778946253946880
collection PubMed
description
format Online
Article
Text
id pubmed-9427618
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher NPS MedicineWise
record_format MEDLINE/PubMed
spelling pubmed-94276182022-09-14 Sacituzumab govitecan for breast cancer Aust Prescr New Drugs NPS MedicineWise 2022-07-07 2022-08 /pmc/articles/PMC9427618/ /pubmed/36110167 http://dx.doi.org/10.18773/austpresr.2022.042 Text en (c) NPS MedicineWise https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives (CC BY-NC-ND) 4.0 License.
spellingShingle New Drugs
Sacituzumab govitecan for breast cancer
title Sacituzumab govitecan for breast cancer
title_full Sacituzumab govitecan for breast cancer
title_fullStr Sacituzumab govitecan for breast cancer
title_full_unstemmed Sacituzumab govitecan for breast cancer
title_short Sacituzumab govitecan for breast cancer
title_sort sacituzumab govitecan for breast cancer
topic New Drugs
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9427618/
https://www.ncbi.nlm.nih.gov/pubmed/36110167
http://dx.doi.org/10.18773/austpresr.2022.042